Voyager receives $30 million up front with potential option exercise fees and milestone payments of up to $600 million plus product sales-based royalties Pfizer receives transgene-specific access to Voyager’s novel AAV capsids with enhanced blood-brain-barrier penetration and cardiac muscle tropism

Reader Interactions

Leave A Reply